Abstract: Provided herein are compounds of Formula (I), compositions comprising the same, and methods of using the same, including use in treating various diseases and conditions, e.g., those caused by axonal degeneration.

Abstract: The present invention relates to a composition analysis technology of ultramicro-volume liquid by laser ablation plasma mass spectrometry. Using a pipette gun to extract the liquid to be detected in a low-temperature environment, dropping the liquid into a dropping pit in a dropping plate, the liquid level is slightly higher than an overflow table in the dropping plate; dropping different liquid samples into different dropping pits by the same method; gradually covering the dropping pit with an analysis film having an area 1.5 times larger than that of the dropping plate from one side of the dropping plate, tightly adhering the thin film onto the dropping plate by using a transparent adhesive tape, the thin film is in close contact with the liquid level; placing the dropping plate covered by the thin film in a LA-ICPMS universal solid sample chamber, and then setting parameters for ablation.

Abstract: The present invention relates to a composition analysis technology of ultramicro-volume liquid by laser ablation plasma mass spectrometry. Using a pipette gun to extract the liquid to be detected in a low-temperature environment, dropping the liquid into a dropping pit in a dropping plate, the liquid level is slightly higher than an overflow table in the dropping plate; dropping different liquid samples into different dropping pits by the same method; gradually covering the dropping pit with an analysis film having an area 1.5 times larger than that of the dropping plate from one side of the dropping plate, tightly adhering the thin film onto the dropping plate by using a transparent adhesive tape, the thin film is in close contact with the liquid level; placing the dropping plate covered by the thin film in a LA-ICPMS universal solid sample chamber, and then setting parameters for ablation.

Abstract: A method of preparing a pharmaceutical microsphere, the method including: adding a silica microsphere to an acid, stirring, adding an alkali to neutralize the acid until the pH value of the mixture of the acid and the alkali is 6-7, filtering and collecting a resulting product, washing, drying, and sieving, to yield a pharmaceutical microsphere. Also provided is a method of preparing a pharmaceutical preparation includes coating the pharmaceutical microsphere with an isolation layer, a taste-masking layer, a sustained-release layer, or a combination thereof.

Abstract: A pharmaceutical composition, including: an active ingredient-loaded pellet core and a coating layer. The active ingredient of the pellet core is oseltamivir or a pharmaceutically acceptable salt thereof. The active ingredient accounts for between 10 and 40 wt. % of the total weight of the pharmaceutical composition. The coating layer includes a polyacrylic acid resin IV and accounts for between 1 and 50 wt. % of the total weight of the pharmaceutical composition. The pharmaceutical composition has a diameter of between 0.10 and 0.50 mm.

Abstract: A pharmaceutical composition, including: an active ingredient-loaded pellet core and a coating layer. The active ingredient of the pellet core is oseltamivir or a pharmaceutically acceptable salt thereof. The active ingredient accounts for between 10 and 40 wt. % of the total weight of the pharmaceutical composition. The coating layer includes a polyacrylic acid resin IV and accounts for between 1 and 50 wt. % of the total weight of the pharmaceutical composition. The pharmaceutical composition has a diameter of between 0.10 and 0.50 mm.

Abstract: An orally-disintegrating oseltamivir tablet, including: between 10 and 50 wt. % of a taste-masking pellet, between 30 and 80 wt. % of a first filler, between 1 and 6 wt. % of a first adhesive, between 2 and 10 wt. % of a disintegrant, between 0 and 5 wt. % of a flavoring agent, between 0.5 and 2.5 wt. % of a lubricant. The taste-masking pellet includes: an active ingredient-loaded pellet core and a coating layer. The active ingredient of the pellet core is oseltamivir or a pharmaceutically acceptable salt of oseltamivir and accounts for between 10 and 40 wt. % of a total weight of the taste-masking pellet. The coating layer include a polyacrylic acid resin IV and accounts for between 1 and 50 wt. % of the total weight of the taste-masking pellet. The diameter of the taste-masking pellet is between 0.10 and 0.50 mm.

Abstract: A method, a system, and an equipment for implementing the central control of a 2G network electric regulating antenna are disclosed. The embodiment of the method includes: receiving an ID of the electric regulating antenna to be controlled and a control command; determining the 2G network electric regulating antenna according to the ID; and sending the control command by a 3G base station equipment to the 2G network electric regulating antenna to control the 2G network electric regulating antenna. The embodiment of the system includes a control platform and a 3G base station equipment. The embodiment of the equipment includes a memory unit and a control unit.

Abstract: A method, a system, and an equipment for implementing the central control of a 2G network electric regulating antenna are disclosed. The embodiment of the method includes: receiving an ID of the electric regulating antenna to be controlled and a control command; determining the 2G network electric regulating antenna according to the ID; and sending the control command by a 3G base station equipment to the 2G network electric regulating antenna to control the 2G network electric regulating antenna. The embodiment of the system includes a control platform and a 3G base station equipment. The embodiment of the equipment includes a memory unit and a control unit.